AVX 012Alternative Names: AVX-012
Latest Information Update: 08 Nov 2016
At a glance
- Originator Instituto de Neurociencias de Alicante
- Developer Avizorex Pharma
- Class Eye disorder therapies; Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Dry eyes